Skip to Content
Reach blood sugar goals with long-acting insulin. Go >

Canagliflozin Pregnancy and Breastfeeding Warnings

Canagliflozin is also known as: Invokana

Canagliflozin Pregnancy Warnings

In animal studies, drug exposure during periods of animal development corresponding to the late second and third trimesters of human development, showed increased kidney weights and renal pelvic and tubular dilation at doses expected during human exposure. There are no adequate and well-controlled studies in pregnant women. In premenopausal women, metformin therapy may result in ovulation in some anovulatory women. AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

Not recommended during the second and third trimesters AU TGA pregnancy category: C US FDA pregnancy category: Not Assigned Risk Summary: Based on adverse renal effects in animals, this drug is not recommended during the second and third trimesters of pregnancy. Comments: -There are risk to mother and fetus associated with poorly controlled diabetes in pregnancy.

See references

Canagliflozin Breastfeeding Warnings

Not recommended Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: -Because of the potential for serious adverse reactions in the nursing infant, breastfeeding is not recommended while taking this drug.

Upon administering radiolabeled canagliflozin to lactating rats, a milk to plasma ratio of 1.4 was found indicating that canagliflozin may be transferred into milk at a concentration comparable to that in plasma. Since human kidney maturation occurs in utero and during the first 2 years of life (when lactational exposure may occur), there may be a risk to the developing human kidney. A risk to the developing rat kidney (renal pelvic and tubular dilations) was observed when juvenile rats were exposed to canagliflozin during maturation.

See references

References for pregnancy information

  1. "Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals, Titusville, NJ.
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

  1. "Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals, Titusville, NJ.
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide